RAC1 and cancer: We then analyzed the effects of either treatment on the signaling pathways downstream to PI3K which are commonly triggered by integrins in cancer cells [50], focusing on Akt and the small GTPase Rac-1, which we already showed to be preferentially activated downstream to hERG1 [36].